Personalized nanomedicine

Clinical Cancer Research

Volumn 18, Issue 18, 2012, Pages 4889-4894

  Lammers, Twan ^a,b,c   Rizzo, Larissa Y ^a   Storm, Gert ^b,c   Kiessling, Fabian ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ASIALOGLYCOPROTEIN RECEPTOR; BLEOMYCIN; CETUXIMAB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GALACTOSAMINE; IMATINIB; LIPOSOME; MACROGOL; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; PACLITAXEL; TRASTUZUMAB; VINCRISTINE;

BREAST CANCER; BREAST METASTASIS; CANCER STAGING; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIGESTIVE SYSTEM CANCER; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG TARGETING; ECHOGRAPHY; EX VIVO STUDY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INDIVIDUALIZATION; KAPOSI SARCOMA; LIVER CELL CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; MULTIPLE MYELOMA; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PARTICLE SIZE; PATIENT CARE; PATIENT MONITORING; PATIENT SELECTION; PERSONALIZED MEDICINE; PERSONALIZED NANOMEDICINE; PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TREATMENT RESPONSE; UNITED STATES;

HUMANS; INDIVIDUALIZED MEDICINE; NANOMEDICINE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84866353910     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1414     Document Type: Review

References (32)

1. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med 2010;363:301-4.
2. Van 't Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 2008;452: 564-70.
3. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005;352:2285-93.
4. Lesko LJ, Woodcock J. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nat Rev Drug Discov 2004;3:763-9.
5. De Groot JF, Sulman EP, Aldape KD. Multigene sets for clinical application in glioma. J Natl Compr Canc Netw 2011;9:449-56.
6. Trusheim MR, Berndt ER, Douglas FL. Strati fied medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 2007;6:287-93.
7. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature 2008;452:580-9.
8. Perik PJ, Lub-De Hooge MN, Gietema JA, van der Graaf WT, de Korte MA, Jonkman S, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2006;24:2276-86.
9. Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 2010;87:586-92.
10. Orlova A, Wallberg H, Stone-Elander S, Tolmachev V. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med 2009;50:417-25.
11. Aerts HJ, Dubois L, Perk L, Vermaelen P, van Dongen GA, Wouters BG, et al. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med 2009;50:123-31.
12. Papadopoulos N, Kinzler KW, Vogelstein B. The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. Nat Biotechnol 2006;24:985-95.
13. Lammers T, Kiessling F, Hennink WE, Storm G. Nanotheranostics and image-guided drug delivery: current concepts and future directions. Mol Pharmaceut 2010;7:1899-912.
14. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004;303:1818-22.
15. Wagner V, Dullaart A, Bock AK, Zweck A. The emerging nanomedicine landscape. Nat Biotechnol 2006;24:1211-7.
16. Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol Pharmaceut 2011;8:2101-41.
17. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008;14:1310-6.
18. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008;7:771-82.
19. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010;7:653- 64.
20. Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release 2012;161:175-87.
21. Seymour LW, Ferry DR, Anderson D, Hesslewood S, Julyan PJ, Poyner R, et al. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol 2002;20:1668-76.
22. Harrington KJ, Mohammadtaghi S, Uster PS, Glass D, Peters AM, Vile RG, et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 2001;7:243-54.
23. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumour vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000;65:271-84.
24. Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Fried-man- Kien A, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 2005;16:2445-51.
25. Laverman P, Boerman OC, Oyen WJG, Corstens FHM, Storm G. In vivo applications of PEG liposomes: unexpected observations. Crit Rev Ther Drug Carrier Syst 2001;18:551-66.
26. Lammers T, Aime S, Hennink WE, Storm G, Kiessling F. Theranostic nanomedicine. Acc Chem Res 2011;44:1029-38.
27. Chauhan VP, Stylianopoulos T, Martin JD, Popovic Z, Chen O, Kamoun WS, et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol 2012;7:383-8.
28. Ponce AM, Viglianti BL, Yu D, Yarmolenko PS, Michelich CR, Woo J, et al. Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. J Natl Cancer Inst 2007;99:53-63.
29. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005;5:161-71.
30. Ferrari M, Philibert MA, Sanhai WR. Nanomedicine and society. Clin Pharmacol Ther 2009;85:466-7.
31. Dittrich PS, Manz A. Lab-on-a-chip: microfluidics in drug discovery. Nat Rev Drug Discov 2006;5:210-8.
32. Editorial. What happened to personalized medicine? Nat Biotechnol 2012;30:1.